Sanofi joins J&J, Eli Lilly in proposing 340B rebate model Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs ...

Sanofi’s lawsuit cites a recent court victory for the drugmaker in another 340B case over hospitals’ use of contract pharmacies to distribute discounted drugs.

“Sanofi has long advocated for changes to the 340B Program, which has been plagued by insufficient HRSA oversight and well-documented misuse,” the company said in a Dec. 17 statement sent to ...

Sanofi joins Johnson & Johnson, Eli Lilly and Bristol Myers Squibb, each of which has filed similar lawsuits in the U.S. District Court for the District of Columbia after rebuffed 340B rebate ...

The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription ... Sanofi, Eli ...

Sanofi has filed a lawsuit accusing the Biden administration of unlawfully preventing the company from changing payment terms to some hospitals that participate in a federal drug discount program ...

Sanofi plans to implement a credit model for 340B drugs starting January 6, 2025, requiring entities to pay WAC prices upfront. HRSA warns this model violates the 340B statute and could result in ...

Currently, drugmakers typically provide 340B discounts at the time of purchase. Sanofi will verify that the patient receiving the drug fits within the definition of eligibility written by the ...

Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

The move came after Sanofi disclosed last month that, as of Jan. 6, certain hospitals covered by the 340B Drug Discount Program would receive credits for medicines ordered at full price from a ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...

A spokesperson for Sanofi confirmed plans to implement a similar model as those proposed by Johnson & Johnson and Eli Lilly — to give hospitals rebates for eligible drugs in program, called 340B ...